The capital raised is to advance the development of XEN-D0501, an oral TRPV1 inhibitor targeting obesity.
About Pila Pharma
A biotech company focused on developing oral therapies for obesity using TRPV1 inhibitors.
Malmö, Sweden-Denmark
Read Company Profile
Source: https://www.startbase.de/news/pila-pharma-sammelt-kapital-fuer-neue-orale-adipositas-therapie/
Frequently Asked Questions
What type of funding round did Pila Pharma raise?
Pila Pharma raised a unspecified round.
How much did Pila Pharma raise in its unspecified?
Pila Pharma raised $1,800,000 EUR in its unspecified.
When did Pila Pharma raise its unspecified?
Pila Pharma raised its unspecified on 2025-07-14.
What was Pila Pharma's valuation after the unspecified?
Pila Pharma was valued at $0 unspecified after the unspecified.
What type of investment was Pila Pharma's unspecified?
Pila Pharma's unspecified was a equity investment.
How will Pila Pharma use the funds from its unspecified?
Pila Pharma plans to use the funds for: Expansion of clinical pipeline for obesity studies, Preclinical studies in rats, Clinical trials in overweight individuals, Preparation for Phase-2a study in Type 2 diabetics.